tradingkey.logo

10X Genomics Inc

TXG
View Detailed Chart
12.640USD
-0.110-0.86%
Close 10/06, 16:00ETQuotes delayed by 15 min
1.57BMarket Cap
LossP/E TTM

10X Genomics Inc

12.640
-0.110-0.86%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.86%

5 Days

+11.46%

1 Month

-9.46%

6 Months

+69.21%

Year to Date

-11.98%

1 Year

-36.86%

View Detailed Chart

TradingKey Stock Score of 10X Genomics Inc

Currency: USD Updated: 2025-10-03

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

10X Genomics Inc's Score

Industry at a Glance

Industry Ranking
48 / 207
Overall Ranking
128 / 4706
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 19 analysts
Buy
Current Rating
15.000
Target Price
+17.65%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

10X Genomics Inc Highlights

StrengthsRisks
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.28% year-on-year.
Fairly Valued
The company’s latest PE is -18.33, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 119.36M shares, decreasing 12.19% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 13.89M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.35.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

10X Genomics Inc Info

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Ticker SymbolTXG
Company10X Genomics Inc
CEOMr. Serge Wilson Saxonov, Ph.D.
Websitehttps://www.10xgenomics.com/
KeyAI